SRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has
advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down
before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful
for liver metabolic disorders from a genetic basis.
SRZN has been...
Key Highlights:
Positive Phase 2 Study: Celldex Therapeutics revealed positive outcomes from a Phase 2 study of Barzolvolimab, focusing on patients with moderate to severe chronic spontaneous urticaria (CSU) refractory.
Well-Tolerated and Favorable Safety Profile: Barzolvolimab demonstrated general well-tolerance and exhibited a favorable safety profile in the...
Nektar and Bristol-Myers Squibb announced today the companies have agreed to a new joint development plan to advance bempegaldesleukin (bempeg) plus Opdivo (nivolumab) into multiple new registrational trials (source: Yahoo Finance).
The 19% jump is making Nektar trading around its fair value. Likely, profit-taking will take place in the next sessions. I'm...
